Precio BioRestorative Therapies Inc (BRTX)

BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. The company is headquartered in Melville, New York and currently employs 11 full-time employees. The company went IPO on 2001-07-11. The firm has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. The company has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The firm is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. The company also operates a commercial biocosmeceutical platform.